课题基金 / 基金详情

Role of L1-CAM in Melanoma Progression and Agiogenesis

Role of L1-CAM in Melanoma Progression and Agiogenesis
L1-CAM 在黑色素瘤进展和血管生成中的作用
批准号:
6679134
负责人:
ANTHONY Michael MONTGOMERY
金额:
$22.05万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-03-01 至 2008-07-31

项目摘要

项目成果

ANTHONY Michael MONTGOMERY的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):细胞粘附分子对肿瘤的发展有深远的影响,可有效促进或抑制恶性疾病的发展。L1(或L1- cam)是一种在神经外胚层肿瘤中过表达的神经细胞粘附分子。在恶性黑色素瘤中,l1的表达与转移性疾病的发展相关。最近的证据表明,L1可能促进肿瘤的血管化,促进黑色素瘤细胞的存活和侵袭。目的是确定L1在黑色素瘤进展中的作用。这项工作将解决我们知识上的重大空白,并将确定L1是否是治疗干预的合适靶点。有三个目的:目的1:L1被提出导致信号通路的激活,从而诱导恶性黑色素瘤的高度运动性和侵袭性表型。这种表型的诱导是。进一步提出了由L1和整合素直接合作的结果。这一目的将验证l1 -整合素直接相互作用导致激活促进黑色素瘤细胞运动、侵袭和基因转录的信号通路的假设。基于初步数据,重点将放在与“进展相关”整合素alphavbeta3的相互作用以及丝裂原活化蛋白激酶(MAPK)途径的贡献上。目标2:动物研究将直接评估L1对黑色素瘤存活、生长和转移的贡献。转移将在实验性肺转移模型中进行评估,而肿瘤细胞的存活和生长将在皮肤微环境中进行评估。进一步的研究将验证L1通过稳定肿瘤-血小板相互作用或通过促进宿主血管的迁移来促进转移的假设。目的3:目的是证明L1切割产物有助于恶性黑色素瘤的血管化。我们已经确定了两个L1片段,它们是由黑色素瘤细胞作为Iosttranslational切割的结果而释放的。这些裂解产物将被测试其促血管生成活性和促进肿瘤血管形成的能力。将确定促血管生成机制。
英文摘要
DESCRIPTION (provided by applicant): Cell adhesion molecules have a profound influence on cancer development, effectively promoting or repressing the development of malignant disease. L1 (or L1-CAM) is a neural cell adhesion molecule that is overexpressed in neuroectodermal tumors. In malignant melanoma, L1-expression correlates with the development of metastatic disease. Recent evidence suggests that L1 may promote the vascularization of tumors and facilitate melanoma cell survival and invasion. The objective is to define the role of L1 in melanoma progression. This work will address a significant gap in our knowledge and will determine whether L1 is a suitable target for therapeutic intervention. There are three aims: AIM #1: L1 is proposed to result in the activation of signaling pathways that induce a highly motile and invasive phenotype in malignant melanoma. Induction of this phenotype is. further proposed to result from direct co-operation between L1 and integrins. This aim will test the hypothesis that direct L1-integrin interaction results in the activation of signaling pathways that promote melanoma cell motility, invasion, and gene transcription. Based on preliminary data, emphasis will be placed on interactions with the 'progression related' integrin alphavbeta3 and on the contribution of the mitogen-activated protein kinase (MAPK) pathway. AIM#2: Animal studies will directly assess the contribution of L1 to melanoma survival, growth, and metastasis. Metastasis will be evaluated in an experimental pulmonary metastasis model, while tumor cell survival and growth will be assessed in the dermal microenvironment. Further studies will test the hypothesis that L1 can promote metastasis by stabilizing tumor-platelet interactions or by promoting migration across the host vasculature. AIM #3: The goal is to demonstrate that L1 cleavage products contribute to the vascularization of malignant melanoma. We have identified two L1 fragments that are released by melanoma cells as a result of Iosttranslational cleavage. These cleavage products will be tested for proangiogenic activity and for their ability to promote tumor vascularization. Proangiogenic mechanisms will be identified.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NOVEL ROLES FOR L1-CAM IN VASCULAR AND IMMUNE PROCESSES
  • 批准号:
    2835645
  • 项目类别:
  • 资助金额:
    $12.8万
  • 财政年份:
    1999
  • 负责人:
    ANTHONY Michael MONTGOMERY
  • 依托单位:
NOVEL ROLES FOR L1-CAM IN VASCULAR AND IMMUNE PROCESSES
  • 批准号:
    6537572
  • 项目类别:
  • 资助金额:
    $27.9万
  • 财政年份:
    1999
  • 负责人:
    ANTHONY Michael MONTGOMERY
  • 依托单位:
NOVEL ROLES FOR L1-CAM IN VASCULAR AND IMMUNE PROCESSES
  • 批准号:
    6184805
  • 项目类别:
  • 资助金额:
    $23.44万
  • 财政年份:
    1999
  • 负责人:
    ANTHONY Michael MONTGOMERY
  • 依托单位:
NOVEL ROLES FOR L1-CAM IN VASCULAR AND IMMUNE PROCESSES
  • 批准号:
    6390326
  • 项目类别:
  • 资助金额:
    $27.09万
  • 财政年份:
    1999
  • 负责人:
    ANTHONY Michael MONTGOMERY
  • 依托单位:
国内基金
海外基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈凌
  • 依托单位: